Sugi Predict

Sugi Predict / Compounds / SCHEMBL144552

SCHEMBL144552

SCHEMBL144552

CN[C@@H]1CC[C@H](c2ccc(Cl)cc2)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.71
▸ KMT2A Q03164 2/20 0.71
▸ NPC1 O15118 1/20 0.71
▸ MLNR O43193 1/20 0.71
▸ NR1I2 O75469 1/20 0.71
▸ ABCB11 O95342 1/20 0.71
▸ ESR1 P03372 1/20 0.71
▸ CYP1A2 P05177 1/20 0.71
▸ CHRM2 P08172 1/20 0.71
▸ CHRM4 P08173 1/20 0.71
▸ ABCB1 P08183 1/20 0.71
▸ ADRB1 P08588 1/20 0.71
▸ CYP3A4 P08684 1/20 0.71
▸ HTR1A P08908 1/20 0.71
▸ CHRM5 P08912 1/20 0.71
▸ ADRA2A P08913 1/20 0.71
▸ ADORA3 P0DMS8 1/20 0.71
▸ CYP2D6 P10635 1/20 0.71
▸ CHRM1 P11229 1/20 0.71
▸ DRD2 P14416 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30244768 1.00 MEN1 (0.71) MEN1KMT2ANPC1MLNRNR1I2
SCHEMBL10991710 1.00 MEN1 (0.71) MEN1KMT2ANPC1MLNRNR1I2
SCHEMBL29690838 1.00 MEN1 (0.71) MEN1KMT2ANPC1MLNRNR1I2
SCHEMBL10991720 1.00 MEN1 (0.71) MEN1KMT2ANPC1MLNRNR1I2
SCHEMBL9843285 1.00 MEN1 (0.71) MEN1KMT2ANPC1MLNRNR1I2
SCHEMBL144554 1.00 MEN1 (0.71) MEN1KMT2ANPC1MLNRNR1I2
SCHEMBL144553 1.00 MEN1 (0.71) MEN1KMT2ANPC1MLNRNR1I2
Hydrochloric Acid SCHEMBL7330576 0.98 MEN1 (0.72) MEN1KMT2ACYP3A4
Hydrochloric Acid SCHEMBL7330587 0.98 MEN1 (0.72) MEN1KMT2ACYP3A4
Hydrochloric Acid SCHEMBL10989815 0.98 MEN1 (0.72) MEN1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0030081-B1 ANTIDEPRESSANT DERIVATIVES OF CIS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF PFIZER INC. (US) 1983-03-02 — — EP claimed
EP-0030081-A1 Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof PFIZER INC. (US) 1981-06-10 — — EP claimed
US-20240026357-A1 MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2024-01-25 — — US disclosed
US-10071163-B2 Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types NLIFE THERAPEUTICS, S.L. (ES) 2018-09-11 — — US disclosed
EP-3231446-A1 COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES Nlife Therapeutics S.L. (ES) 2017-10-18 — — EP disclosed
EP-2560687-B1 COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES NLIFE THERAPEUTICS S L (ES) 2017-05-24 — — EP disclosed
US-20160235856-A1 COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES PALOMO LIMITED (CY) 2016-08-18 — — US disclosed
US-9193969-B2 Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types NLIFE THERAPEUTICS, S.L. (ES) 2015-11-24 — — US disclosed
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 2013-10-31 — — US disclosed
US-8475804-B2 Compositions and methods for treatment of filovirus-mediated diseases U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) 2013-07-02 — — US disclosed
EP-2560687-A2 COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES Nlife Therapeutics S.L. (ES) 2013-02-27 — — EP disclosed
US-20050119160-A1 Methods and reagents for the treatment of immunoinflammatory disorders ZALICUS INC. 2005-06-02 — — US disclosed
WO-2005025563-A1 COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS WARNER-LAMBERT COMPANY LLC (US) 2005-03-24 — — WO disclosed
US-20050059654-A1 Method for treatment of depression and anxiety disorders by combination therapy ARNERIC STEPHEN P (US) 2005-03-17 — — US disclosed
US-20040229849-A1 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines COMBINATORX, INCORPORATED 2004-11-18 — — US disclosed
US-20040224876-A1 Combination therapy for the treatment of immunoinflammatory disorders COMBINATORX, INCORPORATED 2004-11-11 — — US disclosed
US-20040220153-A1 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines COMBINATORX, INCORPORATED 2004-11-04 — — US disclosed
US-4536518-A Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine PFIZER INC. (US) 1985-08-20 — — US disclosed
EP-0030081-B1 ANTIDEPRESSANT DERIVATIVES OF CIS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF PFIZER INC. (US) 1983-03-02 — — EP disclosed
EP-0030081-A1 Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof PFIZER INC. (US) 1981-06-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059654-A1 Method for treatment of depression and anxiety disorders by combination therapy SLC6A2, SLC18A2, ADRA2C MEN1 4090/4885KMT2A 1893/4885NPC1 382/4885
US-10071163-B2 Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types SLC6A2, SLC18A2, SLC1A1 MEN1 2203/4885KMT2A 2436/4885NPC1 208/4885
US-20160235856-A1 COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES SLC6A2, SLC18A2, SLC1A1 MEN1 2203/4885KMT2A 2436/4885NPC1 208/4885
US-20040224876-A1 Combination therapy for the treatment of immunoinflammatory disorders HLA-DRB1, TSLP, SERPINA6 MEN1 3969/4885KMT2A 4265/4885NPC1 398/4885
US-20240026357-A1 MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME METTL16, SYNCRIP, FBL MEN1 767/4885KMT2A 752/4885NPC1 2651/4885
US-20040220153-A1 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines TNF, IL5, IL6 MEN1 3415/4885KMT2A 3563/4885NPC1 1758/4885
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES FLNA, FLNB, PIGS MEN1 3612/4885KMT2A 3886/4885NPC1 366/4885
US-20040229849-A1 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines TNF, IL5, IL6 MEN1 3415/4885KMT2A 3563/4885NPC1 1758/4885
US-20050119160-A1 Methods and reagents for the treatment of immunoinflammatory disorders IL5, TPMT, TSLP MEN1 4127/4885KMT2A 3089/4885NPC1 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.